Antipsychotic switching in schizoaffective disorder: A systematic review

The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
Andrea MurruEduard Vieta

Abstract

To systematically review the evidence about the switching of antipsychotics in SZA in acute and maintenance treatment. A systematic review following the PRISMA statement identifying studies specifically conducted on, or including, SZA patients. One analysis considered uniquely a SZA population, 13 more studies including an adequate SZA subsample were considered. Most of the studies were aimed at switching antipsychotic treatments to improve tolerability issues. Despite the absolute lack of trials specifically conducted on SZA populations, we found limited evidence on the use of aripiprazole, lurasidone, and, to a lesser extent, risperidone and ziprasidone as possible agents to substitute previous treatments whereas efficacy or, more frequently, tolerability issues arise. Evidence supports also the switch to risperidone long-acting injectable when the adherence to oral treatment may be a concern. Antipsychotic switching in SZA is a neglected topic that would need better profiling. Clinicians should keep in mind the receptor binding characteristics of drugs in order to optimize transitions. Evidence supports the switch to aripiprazole and lurasidone, less strongly to risperidone and ziprasidone. The switch to risperidone long-act...Continue Reading

References

Dec 1, 1995·Psychiatric Services : a Journal of the American Psychiatric Association·S KentP Yellowlees
Feb 17, 2000·The Annals of Pharmacotherapy·P S Masand, S L Berry
Mar 1, 2003·Psychopharmacology·Daniel E CaseyUNKNOWN Aripiprazole Study Group
Sep 8, 2005·Journal of Psychopharmacology·A MohlR Medori
May 3, 2006·Journal of Affective Disorders·F ColomJ Sánchez-Moreno
Sep 7, 2007·Journal of Affective Disorders·A R RosaF Kapczinski
Nov 11, 2008·Schizophrenia Research·Robert A RosenheckJeffrey Lieberman
Jul 23, 2009·BMJ : British Medical Journal·David MoherUNKNOWN PRISMA Group
May 11, 2010·Neuropsychobiology·Alessandra M A NivoliEduard Vieta
Jul 22, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·C U Correll
Aug 6, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wolfgang GaebelEnrico Smeraldi
Oct 7, 2010·The Journal of Clinical Psychiatry·Elliott Richelson
Oct 12, 2010·Psychiatry Investigation·Jung-Sun LeeChang Yoon Kim
Dec 15, 2010·CNS Spectrums·Christoph U Correll
Feb 4, 2011·European Psychiatry : the Journal of the Association of European Psychiatrists·A MurruE Vieta
May 14, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·A MurruE Vieta
Oct 18, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Dina PopovicEduard Vieta
Apr 17, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Eduard VietaAndreas Schreiner
Sep 13, 2012·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Hoda MoteshafiEmmanuel Stip
Sep 26, 2012·Psychotherapy and Psychosomatics·Andrea MurruEduard Vieta
Dec 12, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN WFSBP Task force on Treatment Guidelines for Schizophrenia
Jan 5, 2013·The American Journal of Psychiatry·Robert FreedmanJoel Yager
Mar 14, 2013·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Heinz GrunzeUNKNOWN WFSBP Task Force on Treatment Guidelines for Bipolar Disorders
May 15, 2013·The International Journal of Neuropsychopharmacology·Eduard VietaFrank Bellivier
Oct 9, 2013·Journal of Affective Disorders·A MurruF Colom
Oct 22, 2013·The International Journal of Neuropsychopharmacology·Iria GrandeEduard Vieta
Nov 21, 2013·CNS Spectrums·Thomas L Schwartz
Dec 18, 2013·The Journal of Clinical Psychiatry·John W NewcomerRobert W Buchanan

❮ Previous
Next ❯

Citations

May 6, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Isabella PacchiarottiEduard Vieta
Jul 30, 2019·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Young Sup WooWon-Myong Bahk
Apr 23, 2019·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·D F KhritininE P Shchukina
Jul 1, 2019·European Psychiatry : the Journal of the Association of European Psychiatrists·Andrea MurruEduard Vieta
Jan 19, 2021·Acta Psychiatrica Scandinavica·I PacchiarottiE Vieta
Apr 4, 2021·Pharmaceuticals·Valeria CalsolaroFabio Monzani
Dec 8, 2021·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·D F ChritininV D Morozova

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina
João Paulo Maia-de-OliveiraJaime E C Hallak
Neuropsychiatric Disease and Treatment
Mário Rodrigues LouzãJosé Carlos Appolinário
© 2022 Meta ULC. All rights reserved